Phaseline

Targets › PTGER3

PTGER3 (Prostaglandin E2 receptor EP3 subtype): drug programs, companies and trials

8 programs from 8 companies in 8 trials: 4 Phase 4, 2 Phase 2, 1 Phase 1, 1 Phase 3; Other, Gastroenterology, Oncology; next expected readout Dec 2026.

Receptor for prostaglandin E2 (PGE2). The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium. (UniProt, P43115)

Open in Phaseline: the race on PTGER3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Northwestern UniversityMisoprostol
Prostanoid EP3 receptor agonist
PTGER3Phase 4Fibroids, UterineDec 2026
Chinese University of Hong KongMisoprostol
Prostanoid EP3 receptor agonist
PTGER3Phase 4Active Peptic Ulcer Disease/GI BleedingDec 2026
HaEmek Medical Center, IsraelDinoprostone
Prostaglandin E2 receptor agonist
PTGER1, PTGER4, PTGER2, PTGER3Phase 4Induction of LaborJan 2027
Kafrelsheikh UniversityMisoprostol
Prostanoid EP3 receptor agonist
PTGER3Phase 4Misoprostol–
Stony Brook UniversityMisoprostol
Prostanoid EP3 receptor agonist
PTGER3Phase 3Postpartum HemorrhageJan 2027
Ghufran Dhari AwadProstaglandin E1
Prostaglandin E1 receptor agonist
PTGER1, PTGER2, PTGER3, PTGER4Phase 2Accelerated Orthodontic Tooth MovementDec 2026
Indiana Universitymisoprostol
Prostanoid EP3 receptor agonist
PTGER3Phase 2PregnancyDec 2027
Montefiore Medical CenterMisoprostol
Prostanoid EP3 receptor agonist
PTGER3Phase 1Cervical PreparationJun 2027

Conditions

Accelerated Orthodontic Tooth Movement (1) Cervical Preparation (1) Postpartum Hemorrhage (1) Induction of Labor (1) Active Peptic Ulcer Disease/GI Bleeding (1) Fibroids, Uterine (1) Misoprostol (1) Pregnancy (1)

Modalities

small molecule (8)

Companies

Ghufran Dhari Awad (1) Montefiore Medical Center (1) Stony Brook University (1) HaEmek Medical Center, Israel (1) Chinese University of Hong Kong (1) Northwestern University (1) Kafrelsheikh University (1) Indiana University (1)

Related targets

PTGER1 (2) PTGER2 (2) PTGER4 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.